VASCULOPATHY, APOPTOSIS AND AUTOIMMUNITY

这一建议是集中在分子机制的血管病变导致纤维化和自身免疫性表现的系统性硬化症。系统性硬化症患者产生的自身抗体是唯一针对核蛋白的，如DNA拓扑异构酶I （topo-I）。已经证明，topo- 1是凋亡过程特异性蛋白酶的底物，导致新的裂解片段可能揭示宿主以前不耐受的隐表位。最近也有研究表明，弥漫性硬皮病中靶向的几种自身抗原特别容易被金属催化的氧化反应裂解，类似于在缺血-再灌注中存在适当金属时可能发生的反应。这一过程也可能揭示免疫隐表位，并为为什么某些蛋白质是系统性硬化症免疫反应的唯一目标提供了分子解释。然而，众所周知，单独的隐表位不足以产生自身反应性，这还需要分子佐剂的参与，并由具有共刺激能力的抗原提呈细胞（APC）摄取潜在的自身抗原。该建议的中心假设是，系统性硬化症患者的慢性缺血再灌注损伤不仅在皮肤来源的核仁自身抗原内产生免疫隐性表位，而且还产生补体配体，提供打破免疫耐受所需的分子佐剂。本研究的具体目的是：1)确定携带补体的凋亡泡调节细胞因子表达和抗原提呈细胞共刺激能力的能力；2)表征对含有自身抗原的凋亡泡的免疫反应；3)检测补体配体C3d在体外诱导自身反应性T细胞和B细胞对topo I的反应中的作用。虽然系统性硬化症是本研究的重点，但这些研究产生的数据应该为我们对血管病变和自身免疫过程的理解提供深入的见解。

This proposal is focused upon the molecular mechanism by which vasculopathy leads to fibrotic and autoimmune manifestations of systemic sclerosis. Autoantibodies generated by patients with systemic sclerosis are uniquely targeted to nucleolar proteins such as DNA topoisomerase I (topo-I). It has been demonstrated that topo-I is a substrate for protease(s) specific to the apoptotic process, resulting in novel cleavage fragments that may reveal cryptic epitopes to which the host has not previously been tolerized. It has also been recently demonstrated that several of the autoantigens targeted in diffuse scleroderma are uniquely susceptible to cleavage by metal-catalyzed oxidation reactions similar to what may occur during ischemia-reperfusion in the presence of appropriate metals. This process may also reveal immunocryptic epitopes and provides a molecular explanation for why certain proteins are uniquely targeted by the immune response in systemic sclerosis. However, it is well known that a cryptic epitope alone is not sufficient to generate autoreactivity, which also requires the participation of a molecular adjuvant, and uptake of the potential autoantigen by an antigen presenting cell (APC) with costimulatory capacity. The central hypothesis of this proposal is that chronic ischemia-reperfusion injury in patients with systemic sclerosis not only generates immunocryptic epitopes within nucleolar autoantigens of cutaneous origin, but it also generates complement ligands that provide the molecular adjuvant required to break immune tolerance. The specific aims of this proposal are to: 1) Determine the capacity of apoptotic blebs bearing complement ligands to modulate the cytokine expression and costimulatory capacity of antigen presenting cells, 2) characterize the immune responses to self antigen- containing apoptotic blebs, and 3) examine the role of complement ligand C3d during induction of autoreactive T and B cell responses to topo I in vitro. Although systemic sclerosis is the focus of this proposal, the data generated by these studies should provide insight into our understanding of vasculopathic and autoimmune processes in general.